Captrust Financial Advisors Raises Stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Captrust Financial Advisors increased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 19.4% during the third quarter, according to its most recent filing with the SEC. The fund owned 16,274 shares of the biotechnology company’s stock after buying an additional 2,644 shares during the quarter. Captrust Financial Advisors’ holdings in BioCryst Pharmaceuticals were worth $124,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in BCRX. CWM LLC boosted its holdings in shares of BioCryst Pharmaceuticals by 200.0% in the 2nd quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock worth $35,000 after buying an additional 3,772 shares during the last quarter. Signaturefd LLC boosted its position in BioCryst Pharmaceuticals by 560.5% during the second quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 5,599 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its position in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares during the period. nVerses Capital LLC bought a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $63,000. Finally, DRW Securities LLC bought a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $74,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on BCRX. Needham & Company LLC restated a “buy” rating and issued a $14.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $15.60.

BioCryst Pharmaceuticals Price Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.46 on Tuesday. BioCryst Pharmaceuticals, Inc. has a 1 year low of $4.03 and a 1 year high of $8.88. The firm has a market cap of $1.55 billion, a PE ratio of -12.23 and a beta of 1.79. The company has a 50 day simple moving average of $7.61 and a two-hundred day simple moving average of $7.41.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, hitting the consensus estimate of ($0.07). The business had revenue of $117.10 million for the quarter, compared to analysts’ expectations of $113.99 million. The company’s revenue was up 35.1% compared to the same quarter last year. During the same period last year, the business posted ($0.19) earnings per share. As a group, research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.38 earnings per share for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.